Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028The Motley Fool • 1h
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?The Motley Fool • Wednesday
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?Zacks Investment Research • Monday
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.The Motley Fool • 11/04/26
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.The Motley Fool • 11/02/26
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetZacks Investment Research • 10/30/26
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)Seeking Alpha • 10/29/26
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases24/7 Wall Street • 10/29/26
Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The StockSeeking Alpha • 10/29/26
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • 10/28/26
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 2824/7 Wall Street • 10/25/26
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketZacks Investment Research • 10/23/26
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 10/22/26
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026PRNewsWire • 10/21/26